These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 32926459)

  • 1. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.
    Kulikowski E; Rakai BD; Wong NCW
    Med Res Rev; 2021 Jan; 41(1):223-245. PubMed ID: 32926459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.
    Cai M; Dong J; Li H; Qin JJ
    Curr Med Chem; 2022; 29(25):4391-4409. PubMed ID: 35152859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
    Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
    J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
    Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
    Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromodomain inhibitors and therapeutic applications.
    Gajjela BK; Zhou MM
    Curr Opin Chem Biol; 2023 Aug; 75():102323. PubMed ID: 37207401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
    Shanmugam V; Muthukrishnan S
    J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
    Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
    Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress and structural analyses of domain-selective BET inhibitors.
    Divakaran A; Harki DA; Pomerantz WCK
    Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Segmental Isotope Labelling of an Individual Bromodomain of a Tandem Domain BRD4 Using Sortase A.
    Williams FP; Milbradt AG; Embrey KJ; Bobby R
    PLoS One; 2016; 11(4):e0154607. PubMed ID: 27128490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors.
    Karim RM; Bikowitz MJ; Chan A; Zhu JY; Grassie D; Becker A; Berndt N; Gunawan S; Lawrence NJ; Schönbrunn E
    J Med Chem; 2021 Nov; 64(21):15772-15786. PubMed ID: 34710325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.
    Carrasco K; Montersino C; Derviaux C; Saez-Ayala M; Hoffer L; Restouin A; Castellano R; Casassa J; Roche P; Pasquier E; Combes S; Morelli X; Collette Y; Betzi S
    J Med Chem; 2022 Apr; 65(7):5660-5674. PubMed ID: 35348328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.